The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy

Majid Ghasemi, Maryam Ansari, Keivan Basiri, Vahid Shaigannejad, Majid Ghasemi, Maryam Ansari, Keivan Basiri, Vahid Shaigannejad

Abstract

Background: Considering the dramatic increasing rate of diabetes and consequently its related complications, most importantly diabetic peripheral neuropathy (DPN), challenges regarding proper treatment of DPN and its effect on the quality-of-life and care of diabetic patients, the aim of this current study is to evaluate the effect of intradermal botulinum toxin type A (BTX-A) injections on pain symptoms of patients with diabetic neuropathic pain.

Materials and methods: In this randomized double-blind placebo-controlled clinical trial study, diabetic patients aged <70 years with neuropathic pain in both feet were enrolled. Diabetic neuropathy (DN) in selected patients was diagnosed using DN4 questionnaire and nerve conduction velocity examinations. They randomized in two intervention (BTX-A injection/100 unit, N = 20) and placebo groups (normal saline injection, N = 20). The outcome of injection on diabetic neuropathic pain was assessed using neuropathy pain scale (NPS) and visual analog scale (VAS) score and compared in two studied groups.

Results: There was no significant difference in DN4, NPS and VAS scales of studied population after intervention in the placebo group. Intradermal injection of BTX-A reduced NPS scores for all items except cold sensation (P = 0.05). It reduced DN4 scores for electric shocks, burning, pins and needles and brushing (P < 0.05). According to VAS scale 30% and 0% of patients in intervention and placebo groups have no pain after intervention (P = 0.01).

Conclusion: Intradermal injection of BTX-A is a well-tolerated agent that has a significant effect on DPN pain.

Keywords: Botulinum toxin type A; diabetic peripheral neuropathy; pain.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Consort flow diagram of the clinical trial

References

    1. Tesfaye S. Recent advances in the management of diabetic symmetrical polyneuropathy. J Diabetes Investig. 2010;2:33–42.
    1. Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol. 2005;116:1571–80.
    1. Baron R. Mechanisms of disease: Neuropathic pain – A clinical perspective. Nat Clin Pract Neurol. 2006;2:95–106.
    1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.
    1. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351:48–55.
    1. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain. 2005;118:289–305.
    1. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007;132:237–51.
    1. Ziegler D. Painful diabetic neuropathy: Treatment and future aspects. Diabetes Metab Res Rev. 2008;24(Suppl 1):S52–7.
    1. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: An open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25:1663–76.
    1. Simpson DM, Brown S, Tobias J NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305–13.
    1. Finnerup NB, Sindrup SH, Jensen TS. Recent advances in pharmacological treatment of neuropathic pain. F1000 Med Rep. 2010;2:52.
    1. Sim WS. Application of botulinum toxin in pain management. Korean J Pain. 2011;24:1–6.
    1. Najafi MR, Rashidi I. Antispasmodic effect of botulinum toxin type A on spastic hemiplegia due to cerebrovascular accident. Arch Iran Med. 2003;6:265–8.
    1. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274–83.
    1. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology. 2009;72:1473–8.
    1. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18:S177–81.
    1. Restivo DA, Marchese-Ragona R, Lauria G, Squatrito S, Gullo D, Vigneri R. Botulinum toxin treatment for oropharyngeal dysphagia associated with diabetic neuropathy. Diabetes Care. 2006;29:2650–3.
    1. Hummel M, Geigenberger G, Brand J, Ziegler AG, Füchtenbusch M. New therapeutic approaches to diabetic gastroparesis. Med Klin (Munich) 2008;103:514–8.
    1. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) Pain. 2005;114:29–36.
    1. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain. 2006;22:97–103.
    1. Ranoux D. Botulinum toxin and painful peripheral neuropathies: What should be expected? Rev Neurol (Paris) 2011;167:46–50.
    1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–93.
    1. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167–93.
    1. Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: Insights from animal models. Toxins (Basel) 2010;2:2890–913.
    1. Bach-Rojecky L, Salković-Petrisić M, Lacković Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur J Pharmacol. 2010;633:10–4.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться